论文部分内容阅读
据新华社信息,我国第一支具有完全自主知识产权的乙肝抗原-抗体复合物型治疗性疫苗,目前已完成了临床Ⅱ期第一阶段试验,第二阶段已经启动。因此,我国对乙肝将不仅有预防性疫苗,还会有治疗性疫苗。传统的乙肝疫苗一般只有预防效果,可是对已感染的病人束手无策,治疗性疫苗的长处,是使人体免疫系统产生自身抗体,降低甚至清除体内的乙肝病毒。乙肝治疗上最难解决的问题,就是由于免疫耐受造成
According to Xinhua News Agency, the first hepatitis B antigen-antibody complex therapeutic vaccine with complete independent intellectual property rights in China has now completed the first phase of clinical phase Ⅱ trial and the second phase has been started. Therefore, our country will not only have preventive vaccines against hepatitis B, but also therapeutic vaccines. The traditional hepatitis B vaccine is generally only preventive effect, but the infected patients do nothing, the strengths of the therapeutic vaccine is to make the body's immune system produce autoantibodies, reduce or even eliminate the body's hepatitis B virus. Hepatitis B treatment is the most difficult problem, is due to immune tolerance caused